Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies - guidance (TA669)

NICE do not recommend trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. Cost-effectiveness estimates were much higher than what NICE normally considers an acceptable use of NHS resources.

National Institute for Health and Care Excellence